Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF -V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux±Bini treatment is of clinical relevance. In this prespecified, exploratory biomarker analysis of the BEACON CRC study, we characterize genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis, including whole-exome and -transcriptome tissue sequencing and circulating tumor DNA genomic profiling. Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux. RAS , MAP2K1 and MET alterations were most commonly acquired with Enco+Cetux±Bini, and more frequent in patients with a high baseline cell-cycle gene signature; baseline TP53 mutation was associated with acquired MET amplification. Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux±Bini and mutational signatures (SBS17a/b). These findings support treatment with Enco+Cetux±Bini for patients with BRAF -V600E-mutant mCRC and provide insights into the biology of response and resistance to MAPK-pathway-targeted therapy. ClinicalTrials.gov registration: NCT02928224
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










![Extended Data Fig. 5 Immune gene associations with OS benefit in each treatment arm. a, Associations between OS and immune gene expression (scaled) in each treatment arm were determined by Cox proportional hazards models (two-sided Wald test). Genes in the top quartile of variance in expression (based on IQR and measured in log2[TPM]) were tested. Genes showing an interaction (unadjusted P value < 0.001) for Enco+Cetux vs Control are shown with blue circles and for Enco+Cetux vs Enco+Bini+Cetux (top panel) are shown as red dots across panels. b, Enrichment plots from GSEA against the hallmark IFN-γ gene signature in each treatment arm.](https://figures.cochat.ai/paper-figures/94c2899dd04c4376bdfe0e3c91d71940/molecular-profiling-of-braf-v600e-mutant-metastatic-colorectal-cancer-in-the-figure-11.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The phase III BEACON CRC trial demonstrated improved overall survival with encorafenib plus cetuximab compared to standard chemotherapy [56].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the exploratory biomarker analysis of the BEACON CRC study showed that RAS, MAP2K1, and MET are the most acquired alterations when patients are treated with encorafenib and cetuximab with or without binimetinib, a selective inhibitor of MEK, thus contributing to the therapy resistance [40].”
From Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The BEACON CRC trial led to a combination of encorafenib (BRAF inhibitor) and cetuximab as a standard care of BRAF V600E mCRC, showcasing improvements in overall survival and response rates compared to conventional chemotherapy [56].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“suggesting that these genes could be potential prognostic biomarkers in this patient population [40].”
From Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 56 · Cited by 82
Metadata
- Authors
- Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., Hamilton, P., Xie, T., Yaeger, R., & Tabernero, J.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Pfizer (United States) (US)
- University of Campania "Luigi Vanvitelli" (IT)
- Peter MacCallum Cancer Centre (AU)
- Hammersmith Hospital (GB)
- National Cancer Center Hospital East (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Corresponding author
- Kopetz, Scott
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-09-23
- Volume
- 30
- Issue
- 11
- Pages
- 3261-3271
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11564101
- OpenAlex
- W4402749120
- Cited by
- 82
- References
- 56
- Citations by year
- 2026: 32 · 2025: 48 · 2024: 2
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Pfizer (P30 CA008748)
- Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
- Merck KGaA
- Les Laboratories Pierre Fabre
- Fundació Institut de Recerca Hospital Universitari Vall d’Hebron
- Ono Pharmaceutical
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- BRAF V600E mutation, metastatic colorectal cancer, encorafenib, cetuximab, binimetinib, predictive biomarkers, acquired resistance, MAPK signaling, RAS mutations, MET amplification, MEK1, TP53 mutation, mutational signatures, subclonal mutations, tumor immune signature, circulating tumor DNA, gene expression profiling, exome sequencing
- MeSH terms
- Cetuximab, Antineoplastic Combined Chemotherapy Protocols, Azetidines, Benzimidazoles, Carbamates, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Biomarkers, Tumor, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Gene Expression Profiling, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. https://app.cochat.ai/papers/10.1038/s41591-024-03235-9
- The paper
- Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., Hamilton, P., Xie, T., Yaeger, R., & Tabernero, J. (2024). Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03235-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.